An oral B subunit-whole cell vaccine against cholera: from concept to successful field trial
Holmgren, J.; Svennerholm, A.M.; Clemens, J.; Sack, D.; Black, R.; Levine, M.
Advances in Experimental Medicine and Biology 216b: 1649-1660
1987
ISSN/ISBN: 0065-2598 PMID: 3321938 Document Number: 287068
Document emailed within 1 workday
Related Documents
Svennerholm, A.M.; Jertborn, M.; Gothefors, L.; Karim, A.; Sack, D.A.; Holmgren, J. 1983: Current status of an oral B subunit whole cell cholera vaccine Developments in Biological Standardization 53: 73-79Clemens, J.D.; van Loon, F.F.; Rao, M.; Sack, D.A.; Ahmed, F.; Chakraborty, J.; Khan, M.R.; Yunus, M.; Harris, J.R.; Svennerholm, A.M. 1992: Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines American Journal of Epidemiology 135(8): 865-874
Just, M.; Berger, R.; Glück, R.; Wegmann, A. 1985: Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella Schweizerische Medizinische Wochenschrift 115(48): 1727-1730
Chaicumpa, W.; Chaisri, U.; Tapchaisri, P.; Chongsa-Nguan, M.; Pongponratn, E. 1987: Oral vaccine against cholera prepared from Vibrio cholerae antigen(s) Southeast Asian Journal of Tropical Medicine and Public Health 18(2): 142-148
2014: Oral cholera vaccine campaign among internally displaced persons in South Sudan Releve Epidemiologique Hebdomadaire 89(20): 214-220
Glass, R.I.; Svennerholm, A.M.; Stoll, B.J.; Khan, M.R.; Huda, S.; Huq, M.I.; Holmgren, J. 1989: Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine Pediatric Infectious Disease Journal 8(2): 105-109
Li, Z.-J.; Sun, Q.-Z.; Jing, H.-Q.; Xu, J.-G. 2008: Clone and express ctb-stx2b fusion gene in Enterohemrrhagic escherichia coli O157:H7 Shigeal toxin 2B subunit and V cholera toxin B subunit and the detection of their immunogenicity Zhonghua Liu Xing Bing Xue Za Zhi 29(4): 378-382
Dzhaparidze, M.N.; Naumov, A.V.; Nikitina, G.P.; Meleshchenko, M.V.; Dobrova, G.V.; Zavorotnykh, V.I.; Gracheva, V.P.; Zakharova, T.L. 1991: An oral chemical vaccine from the hypertoxigenic strains of the causative agent of cholera KM-76 Inaba and KM-68 Ogawa Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 4: 31-33
Pascual, D.W.; Powell, R.J.; Lewis, G.K.; Hone, D.M. 1997: Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine Behring Institute Mitteilungen 1997(98): 143-152
Wiedermann, U.; Hanson, L.A.; Holmgren, J.; Dahlgren, U.I. 1995: Impaired mucosal immune response in vitamin a deficient rats immunized with oral cholera vaccine Advances in Experimental Medicine and Biology 371b: 1629-1631
Khatib, A.M.; Ali, M.; von Seidlein, L.; Kim, D.R.; Hashim, R.; Reyburn, R.; Ley, B.; Thriemer, K.; Enwere, G.; Hutubessy, R.; Aguado, M.T.; Kieny, M.-P.; Lopez, A.L.; Wierzba, T.F.; Ali, S.M.; Saleh, A.A.; Mukhopadhyay, A.K.; Clemens, J.; Jiddawi, M.S.; Deen, J. 2012: Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study LANCET. Infectious Diseases 12(11): 837-844
Perry, R.T.; Plowe, C.V.; Koumaré, B.; Bougoudogo, F.; Kotloff, K.L.; Losonsky, G.A.; Wasserman, S.S.; Levine, M.M. 1998: A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali Bulletin of the World Health Organization 76(1): 63-71
Kar, S.K.; Sah, B.; Patnaik, B.; Kim, Y.H.; Kerketta, A.S.; Shin, S.; Rath, S.B.; Ali, M.; Mogasale, V.; Khuntia, H.K.; Bhattachan, A.; You, Y.A.; Puri, M.K.; Lopez, A.L.; Maskery, B.; Nair, G.B.; Clemens, J.D.; Wierzba, T.F. 2014: Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model Plos Neglected Tropical Diseases 8(2): E2629
Vonka, V.; Závadová, H.; Brůj, J.; Skocil, V.; Janout, V.; Uvizl, M.; Kotíková, J. 1977: Small-scale field trial with neuraminidase vaccine Developments in Biological Standardization 39: 337-339
Reber-Liske, R.; Salako, L.A.; Matile, H.; Sowunmi, A.; Stürchler, D. 1995: NANP]19-5.1. A malaria vaccine field trial in Nigerian children Tropical and Geographical Medicine 47(2): 61-63
Ahmed, T.; Svennerholm, A-Mari.; Al Tarique, A.; Sultana, G.N.N.; Qadri, F. 2009: Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding Vaccine 27(9): 1433-1439
Francis, T.; Korns, R.F. 1955: Evaluation of 1954 field trial of poliomyelitis vaccine: synopsis of summary report American Journal of the Medical Sciences 229(6): 603-612
Dezzutti, C.S.; Frazier, D.E.; Huff, L.Y.; Stromberg, P.C.; Olsen, R.G. 1990: Subunit vaccine protects Macaca nemestrina (pig-tailed macaque) against simian T-cell lymphotropic virus type i challenge Cancer Research 50(17 Suppl): 5687s-5691s
Semá Baltazar, C.; Rafael, F.; Langa, Jé.Paulo.M.; Chicumbe, S.; Cavailler, P.; Gessner, B.D.; Pezzoli, L.; Barata, Aérico.; Zaina, D.; Inguane, Déia.L.; Mengel, M.A.; Munier, A. 2018: Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique Plos one 13(10): E0198592
Schmitt-Grohé, S.; Stehr, K.; Cherry, J.D.; Heininger, U.; Uberall, M.A.; Laussucq, S.; Eckhardt, T. 1997: Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group Developments in Biological Standardization 89: 113-118